Abstract
The promyelocytic leukemia protein (PML), involved in the pathogenesis of acute promyelocytic leukemia, is a coactivator of p53 tumor suppressive functions. The ability of PML to inhibit growth and induce cell death in solid tumor cells, however, has not been determined. We therefore assayed the tumor suppressor activities of PML and compared them with those of p53 in four liver cancer cell lines. Following infection of cells with replication-deficient recombinant PML adenovirus, the exogenous PML localized in the nucleus and formed abnormally enlarged PML–nuclear bodies after 24 hours. In vitro growth curve analysis showed that the overexpressed PML initially induced a substantial G1 cell cycle arrest and triggered massive cell death in all tested cell lines, irrespective of their p53 status. PML-induced cell death decreased by about 30% in the presence of a broad caspase inhibitor, zVAD. The cell death effect of PML was higher than that induced by p53 over a longer period of time. As with p53, overexpression of PML was closely related to upregulation of p21 and decrease of cyclin D1 expression. Unexpectedly, retinoic acid (RA) antagonized rather than enhanced PML-triggered cell death. RA enhanced the expression of adenovirus–cytomegalovirus-promoted PML at both transcription and protein levels within 12 hours after treatment; however, the PML protein was significantly degraded in the presence of RA at days 3–5 postinfection. PML degradation was also observed in SK-BR3 breast cancer cells treated with RA. Taken together, our findings strongly support the hypothesis that PML acts as a strong independent cell death inducer and that RA conversely abolishes the therapeutic effects of the PML proteins through proteasomal degradation of the protein.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weis K, Rambaud S, Lavau C, et al. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell. 1994; 76: 345–356.
Ferbeyre G . PML a target of translocations in APL is a regulator of cellular senescence. Leukemia. 2002; 16: 1918–1926.
Ruggero D, Wang ZG, Pandolfi PP . The puzzling multiple lives of PML and its role in the genesis of cancer. Bioessays. 2000; 22: 827–835.
Borden KL . Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol. 2002; 22: 5259–5269.
Le XF, Vallian S, Mu ZM, et al. Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene. 1998; 16: 1839–1849.
He D, Mu ZM, Le X, et al. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. Cancer Res. 1997; 57: 1868–1872.
Guo A, Salomoni P, Luo J, et al. The function of PML in p53-dependent apoptosis. Nat Cell Biol. 2000; 2: 730–736.
Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways. Nat Genet. 1998; 20: 266–272.
Quignon F, De Bels F, Koken M, et al. PML induces a novel caspase-independent death process. Nat Genet. 1998; 20: 259–265.
Fogal V, Gostissa M, Sandy P, et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 2000; 19: 6185–6195.
Yang S, Kuo C, Bisi JE, Kim MK . PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol. 2002; 4: 865–870.
Pitha-Rowe I, Petty WJ, Kitareewan S, Dmitrovsky E . Retinoid target genes in acute promyelocytic leukemia. Leukemia. 2003; 17: 1723–1730.
Higuchi E, Chandraratna RA, Hong WK, Lotan R . Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene. 2003; 22: 4627–4635.
Pandolfi PP . In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene. 2001; 20: 5726–5735.
Wang ZG, Delva L, Gaboli M, et al. Role of PML in cell growth and the retinoic acid pathway. Science. 1998; 279: 1547–1551.
Schneider SM, Offterdinger M, Huber H, Grunt TW . Activation of retinoic acid receptor α is sufficient for full induction of retinoid responses in SK-BR-3 and T47D human breast cancer cells. Cancer Res. 2000; 60: 5479–5487.
Toma S, Isnardi L, Raffo P, et al. RARα antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines. Int J Cancer. 1998; 78: 86–94.
Lain S, Lane D . Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer. 2003; 39: 1053–1060.
McCormick F . Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001; 1: 130–141.
Chartier C, Degryse E, Gantzer M, et al. Efficient generation of recombination adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 1996; 70: 4805–4810.
Lee H, Kim J, Lee B, et al. Oncolytic potential of E1B 55 kDa-deleted YKL-1 recombinant adenovirus: correlation with p53 functional status. Int J Cancer. 2000; 88: 454–463.
Hirao A, Kong YY, Matsuoka S, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 2000; 287: 1824–1827.
Chehab NH, Malikzay A, Appel M, Halazonetis TD . Chk2/hCds1 fuctions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 2000; 14: 278–288.
Häcker G . The morphology of apoptosis. Cell Tissue Res. 2000; 301: 5–17.
Jaeschke H, Lemasters JJ . Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology. 2003; 125: 1246–1257.
Gaetano C, Catalano A, Palumbo R, et al. Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo. Gene Therapy. 2000; 7: 1624–1630.
Nakashima T, Sun SY, Lotan R, et al. All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma. Laryngoscope. 2001; 111: 1459–1464.
Havlik R, Jiao LR, Nicholls J, et al. Gene therapy for liver metastases. Semin Oncol. 2002; 29: 202–208.
Schmitz V, Qian C, Ruiz J, et al. Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies. Gut. 2002; 50: 130–135.
Swisher SG, Roth JA, Komaki R, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003; 9: 93–101.
Salomoni P, Pandolfi PP . The role of PML in tumor suppression. Cell. 2002; 108: 165–170.
Moller A, Sirma H, Hofmann TG, et al. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res. 2003; 63: 4310–4314.
Pearson M, Carbone R, Sebastiani C, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 2000; 406: 207–210.
Zhong S, Salomoni P, Ronchetti S, et al. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med. 2000; 191: 631–640.
Bartolini G, Orlandi M, Ammar K, et al. Effect of a new derivative of retinoic acid on proliferation and differentiation in human neuroblastoma cells. Anticancer Res. 2003; 23: 1495–1499.
Zhu J, Gianni M, Kopf E, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci. 1999; 96: 14807–14812.
Gianni M, Koken MH, Chelbi-Alix MK, et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood. 1998; 91: 4300–4310.
Drexler HC . Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci. 1997; 94: 855–860.
Acknowledgements
This study was supported by Grants (2003-309 and 2004-309) from the Asan Institute for Life Science, Seoul, Korea.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Son, SH., Yu, E., Choi, E. et al. Promyelocytic leukemia protein-induced growth suppression and cell death in liver cancer cells. Cancer Gene Ther 12, 1–11 (2005). https://doi.org/10.1038/sj.cgt.7700755
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700755
Keywords
This article is cited by
-
TRIM proteins in hepatocellular carcinoma
Journal of Biomedical Science (2022)
-
PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses
Gene Therapy (2009)